UY34561A - Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica. - Google Patents
Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica.Info
- Publication number
- UY34561A UY34561A UY0001034561A UY34561A UY34561A UY 34561 A UY34561 A UY 34561A UY 0001034561 A UY0001034561 A UY 0001034561A UY 34561 A UY34561 A UY 34561A UY 34561 A UY34561 A UY 34561A
- Authority
- UY
- Uruguay
- Prior art keywords
- fgfr
- diary
- fgf
- therapeutics
- agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La invención se refiere a nuevos compuestos heterocíclicos derivados de pirazolopiridina inductores de la dimerización de los receptores de los factores de crecimiento de fibroblastos (o FGFR) de la fórmula general: M1-L-M2 en la que M1 o M2 idénticos o diferentes representan cada uno independientemente uno de otro una unidad monómera M y L representa un grupo de enlace que une M1 y M2 de forma covalente con la unidad monómera que sigue: Su procedimiento de preparación y su aplicación en terapéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1162485A FR2985257B1 (fr) | 2011-12-28 | 2011-12-28 | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34561A true UY34561A (es) | 2013-07-31 |
Family
ID=47716121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001034561A UY34561A (es) | 2011-12-28 | 2012-12-28 | Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9034898B2 (es) |
| EP (1) | EP2797917B1 (es) |
| JP (1) | JP6049756B2 (es) |
| KR (1) | KR20140105578A (es) |
| CN (1) | CN104136434B (es) |
| AR (1) | AR089452A1 (es) |
| AU (1) | AU2012360095B2 (es) |
| BR (1) | BR112014015882A8 (es) |
| CA (1) | CA2861718C (es) |
| CY (1) | CY1119301T1 (es) |
| DK (1) | DK2797917T3 (es) |
| ES (1) | ES2602798T3 (es) |
| FR (1) | FR2985257B1 (es) |
| HK (1) | HK1198649A1 (es) |
| HR (1) | HRP20161463T1 (es) |
| HU (1) | HUE029515T2 (es) |
| IL (1) | IL233324A (es) |
| LT (1) | LT2797917T (es) |
| MX (1) | MX356656B (es) |
| PL (1) | PL2797917T3 (es) |
| PT (1) | PT2797917T (es) |
| RU (1) | RU2014131065A (es) |
| SG (1) | SG11201403572RA (es) |
| SI (1) | SI2797917T1 (es) |
| TW (1) | TWI562994B (es) |
| UY (1) | UY34561A (es) |
| WO (1) | WO2013098764A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
| DK2872491T3 (da) | 2012-07-11 | 2021-08-09 | Blueprint Medicines Corp | Inhibitorer af fibroblastvækstfaktorreceptoren |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
| US9850276B2 (en) * | 2013-05-24 | 2017-12-26 | The Scripps Research Institute | Bidentate-binding modulators of LRRK2 and JNK kinases |
| JP6458023B2 (ja) | 2013-10-25 | 2019-01-23 | ブループリント メディシンズ コーポレイション | 繊維芽細胞成長因子受容体の阻害剤 |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| CA3006897A1 (en) | 2017-08-04 | 2019-02-04 | University Health Network | Generation of oligodendrogenic neural progenitor cells |
| US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CN113651810B (zh) * | 2021-07-16 | 2023-10-13 | 上海毕得医药科技股份有限公司 | 一种3-甲酰基-1H-吡唑并[3,4-b]吡啶-5-羧酸甲酯的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| GB0402137D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| FR2896247B1 (fr) * | 2006-01-13 | 2008-02-29 | Sanofi Aventis Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| EP2212333A1 (en) * | 2007-10-16 | 2010-08-04 | Wyeth LLC | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| BR112012003462A2 (pt) * | 2009-08-24 | 2016-02-23 | Ascepion Pharmaceuticals Inc | "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase." |
| FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
| PL3001903T3 (pl) * | 2009-12-21 | 2018-03-30 | Samumed, Llc | 1H-pirazolo[3,4-b]pirydyny i ich zastosowania terapeutyczne |
-
2011
- 2011-12-28 FR FR1162485A patent/FR2985257B1/fr active Active
-
2012
- 2012-12-26 BR BR112014015882A patent/BR112014015882A8/pt not_active Application Discontinuation
- 2012-12-26 WO PCT/IB2012/057727 patent/WO2013098764A1/en active Application Filing
- 2012-12-26 CA CA2861718A patent/CA2861718C/en not_active Expired - Fee Related
- 2012-12-26 AR ARP120104965A patent/AR089452A1/es unknown
- 2012-12-26 HU HUE12824734A patent/HUE029515T2/en unknown
- 2012-12-26 AU AU2012360095A patent/AU2012360095B2/en not_active Ceased
- 2012-12-26 KR KR1020147019813A patent/KR20140105578A/ko not_active Application Discontinuation
- 2012-12-26 ES ES12824734.3T patent/ES2602798T3/es active Active
- 2012-12-26 JP JP2014549609A patent/JP6049756B2/ja active Active
- 2012-12-26 SI SI201230759A patent/SI2797917T1/sl unknown
- 2012-12-26 PL PL12824734T patent/PL2797917T3/pl unknown
- 2012-12-26 DK DK12824734.3T patent/DK2797917T3/en active
- 2012-12-26 MX MX2014007843A patent/MX356656B/es active IP Right Grant
- 2012-12-26 PT PT128247343T patent/PT2797917T/pt unknown
- 2012-12-26 US US14/369,160 patent/US9034898B2/en active Active
- 2012-12-26 EP EP12824734.3A patent/EP2797917B1/en active Active
- 2012-12-26 SG SG11201403572RA patent/SG11201403572RA/en unknown
- 2012-12-26 RU RU2014131065A patent/RU2014131065A/ru not_active Application Discontinuation
- 2012-12-26 CN CN201280070640.9A patent/CN104136434B/zh active Active
- 2012-12-26 LT LTEP12824734.3T patent/LT2797917T/lt unknown
- 2012-12-27 TW TW101150736A patent/TWI562994B/zh not_active IP Right Cessation
- 2012-12-28 UY UY0001034561A patent/UY34561A/es not_active Application Discontinuation
-
2014
- 2014-06-23 IL IL233324A patent/IL233324A/en not_active IP Right Cessation
- 2014-12-02 HK HK14112113.1A patent/HK1198649A1/xx unknown
-
2016
- 2016-11-04 HR HRP20161463TT patent/HRP20161463T1/hr unknown
- 2016-11-09 CY CY20161101150T patent/CY1119301T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34561A (es) | Compuestos dímeros agonistas de los receptores de los fgf (fgfr), su procedimiento de preparación y su aplicación en terapéutica. | |
| UY34560A (es) | Compuestos dímeros agonistas de los receptores de los fgf (fgfr),su proceso de preparación y su aplicación en terapéutica. | |
| UY34502A (es) | Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio | |
| UY33925A (es) | Inhibidores tricíclicos de quinasas | |
| UY34104A (es) | ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?. | |
| UY34559A (es) | Inhibidores de bromodominios | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| UY34145A (es) | Compuestos inhibidores de metaloenzimas | |
| UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| UY34146A (es) | Compuestos inhibidores de metaloenzimas | |
| ECSP13013022A (es) | Agonistas de fgfr1 y sus métodos de uso | |
| UY34156A (es) | Compuestos inhibidores de metaloenzimas | |
| UY34515A (es) | Triazolopiridinas sustituidas | |
| UY34342A (es) | ?derivados de pirrolopirimidina y purina?. | |
| UY33978A (es) | Piridinonas bicíclicas nuevas. | |
| UY34572A (es) | Compuestos heterocíclicos agonistas del receptor ip | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| UY34765A (es) | Compuestos novedosos. | |
| UY34632A (es) | Compuestos de oxazolidin- 2- ona y usos de los mismos | |
| UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
| UY34300A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
| UY33985A (es) | Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida | |
| UY34302A (es) | COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA | |
| UY34034A (es) | Triazolopiridinas | |
| UY34045A (es) | Derivados de imidazopiridina como inhibidores de pi3k |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20201020 |